メニュー

学会発表・講演等

主な国際学会発表

・Hiramoto S, Kato K, Boku N et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in metastatic or recurrent esophageal squamous cell carcinoma. American Society of Clinical Oncology-Gastrointestinal world meeting  (ASCO-GI)(米国臨床腫瘍学会消化管世界会議) 2015 in SanFransisco

・Hiramoto S, Tsuneto S, Yoshioka A et al. Status of prognosis prediction in terminal cancer patients at a Japanese general hospital. 14th World Congress of the European Association for Palliative Care (欧州緩和ケア学会) in Copenhagen 

 ・ Hiramoto S, Maeda I, Yoshioka A. et al. Efficacy of palliative radiation for advanced gastric cancer patients.European Society of Medical Oncology (欧州臨床腫瘍学会) congress 2015 in Wien

・Hiramoto S, Maeda I, Morita T et al. Effect of the primary site on the prognosis with advanced-stage cancer in palliative care settings.  ASCO (米国臨床腫瘍学会) annual meeting 2016 in Chicago →palliative care とend-of-life careのサブカテゴリーでは日本初

・Hiramoto S, Kikuchi A, Yoshioka A et al. A picture of early death after admission in patients with advanced cancer at the end-of-life. ASCO palliative oncology care symposium (米国臨床腫瘍学会緩和ケアシンポジウム) 2017  in SanDiego

・Hiramoto S, Yoshioka A, Inoue A et al. Prognostic impact of end-of-life chemotherapy in the last weeks with advanced cancer. ESMO (欧州臨床腫瘍学会) congress 2018 in Munch

・Hiramoto S, Hori T, Yoshioka A., et al. Associations between primary cancer site, metastatic site, comorbidity, and details of symptoms and treatment in advanced gastrointestinal cancer patients at end-of-life. ESMO (欧州臨床腫瘍学会)GI 2019 in Barcelona

・Hiramoto S, Hori T, Yoshioka A., et al. Association between prognosis and discontinuation by image diagnosis for advanced gastrointestinal cancer patients who received end-of-life chemotherapy. ESMO (欧州臨床腫瘍学会)GI 2019 in Barcelona

・Hiramoto S, Tamaki T, Yoshioka A et al. End-of-life care and prognosis of elderly patients with advanced cancer in palliative care unit. ASCO  annual meeting 2020 in Chicago 

・Hiramoto S, Yoshioka A, Inoue A et al. Effects of molecular targeting agents and immune-checkpoint inhibitors in patients with advanced cancer who are near the end of life. ESMO (欧州臨床腫瘍学会) congress 2020 in Madrid 

・Hiramoto S, Kirishima T, Yoshioka A et al. The frequency and predictors of end-of-life symptom in patients with advanced cancer. ASCO  annual meeting 2021 in Chicago 

・Masuda K, Ishiki H, Hiramoto S et al. Effect of paracentesis on the survival of patients with terminal cancer and ascites: A propensity score-weighted analysis of the EASED study ASCO  annual meeting 2021 in Chicago 

・Hiramoto S, Tokutani R. Clinical factors associated with survival time from the last administration of systemic anticancer therapy to death in patients with advanced cancer. ESMO (欧州臨床腫瘍学会) congress 2021 in Paris

・(Best Poster Abstract) Oya K et al. Simulation training program for the delivery of death pronouncement, 11th World Research Congress of the EAPC, Palermo, Italy(Online), 2020.

・(Best Poster Award) Oya K et al. Association between bathing and survival in patients with advanced cancer in the terminally ill period: a propensity score analysis, The 13th Asia Pacific Hospice Conference, Surabaya, Indonesia, 2019.

 

主な国内学会発表 (シンポジウム)

・平本秀二、菊地綾子、吉岡亮他。オンコロジーと緩和ケアの統合における当院の現状とこれからの課題  第4回サポーティブケア学会シンポジウム 2019

・平本秀二、菊地綾子、吉岡亮他。腫瘍学と在宅ケアの統合におけるサイエンスとアート 第25回日本緩和医療学会シンポジウム 2020

・平本秀二。抗がん剤のやめ時をどう支えるか理論と実践 第26回日本緩和医療学会シンポジウム2021

 

主な講演

平成30年度厚生労働省委託事業 市民公開講座
『あなたを支える緩和ケア~治療も、仕事も、生活も~』

「がん治療と就労問題について考える〜治療医の立場から〜」

平本 秀二氏(三菱京都病院 腫瘍内科・緩和ケア内科 医長)

日本経済新聞掲載

▲ ページのトップに戻る

Close

HOME